Group One Trading, L.P. Inhibrx, Inc. Transaction History

Group One Trading, L.P.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$14.5 - $38.0 $160,457 - $420,508	11,066 Added 691.63%	12,666 $481,000
Q3 2023 Nov 09, 2023	BUY	$15.75 - $26.31 $15,797 - $26,388	1,003 Added 168.01%	1,600 $29,000
Q2 2023 Aug 09, 2023	BUY	$16.96 - $27.82 $10,125 - $16,608	597 New	597 $15,000
Q1 2022 May 12, 2022	SELL	$19.89 - $43.18 $338 - $734	-17 Closed	0 $0
Q4 2021 Feb 11, 2022	BUY	$26.75 - $46.02 $454 - $782	17 New	17 $1,000

25.3K

Ticker INBX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,057,700
Market Cap $617M
Description
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...

Get notified when there are updates to the investment portfolio of Group One Trading, L.P., based on Form 13F filings with the SEC.

Stay updated on Group One Trading, L.P. with notifications on news.